RSS   Newsletter   Contact   Advertise with us
Post Online Media

Mirna Therapeutics appoints Perry Nisen to its board

Perry NisenMirna Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the appointment of Perry Nisen to the company's board of directors.
Dr. Nisen currently serves as the Chief Executive Officer and Donald Bren Chief Executive Chair of the Sanford Burnham Prebys Medical Discovery Institute, an independent biomedical research institute.

Before joining Sanford Burnham Prebys, Dr. Nisen served as Senior Vice President of Science and Innovation at GlaxoSmithKline (GSK), where he facilitated innovation and integration of R&D across GSK's global organization and was integral to the discovery, development, and commercialization of a vast portfolio of drugs.

Earlier in his career at GSK, he held various key positions, including interim Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, and Senior Vice President of Clinical Pharmacology and Discovery Medicine.

Previously, Dr. Nisen was the Divisional Vice President of Cancer Research and Oncology Development at Abbott Laboratories.

Formerly, Dr. Nisen was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. He holds a B.S. from Stanford University and M.D. and Ph.D. from the Albert Einstein College of Medicine.




We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy